Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Teresa Brophy Bair sold 31,487 shares of Kura Oncology stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider directly owned 195,444 shares in the company, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Kura Oncology Trading Up 1.5%
KURA traded up $0.18 during trading on Friday, hitting $11.89. 2,025,795 shares of the company’s stock were exchanged, compared to its average volume of 1,613,393. Kura Oncology, Inc. has a 1 year low of $7.36 and a 1 year high of $12.90. The stock has a 50 day moving average price of $10.48 and a 200 day moving average price of $9.44. The firm has a market cap of $1.06 billion, a P/E ratio of -3.53 and a beta of 0.38. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. As a group, analysts expect that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Report on Kura Oncology
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. IFP Advisors Inc boosted its stake in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. Royal Bank of Canada increased its stake in shares of Kura Oncology by 7.6% in the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock valued at $203,000 after purchasing an additional 1,375 shares during the period. Allworth Financial LP raised its holdings in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares during the last quarter. Focus Partners Advisor Solutions LLC raised its holdings in shares of Kura Oncology by 7.9% during the fourth quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after buying an additional 1,682 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Kura Oncology by 10.0% during the fourth quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock worth $193,000 after buying an additional 1,692 shares during the period.
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Stories
- Five stocks we like better than Kura Oncology
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
